Margherita Ambrosini

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial

Carlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio et al. · The Lancet Oncology · 2022 · 246 citations · Full text

Oncology, Clinical Trials, Colorectal Cancer +9

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

Andrea Sartore‐Bianchi, Filippo Pietrantonio, Sara Lonardi et al. · Nature Medicine · 2022 · 237 citations · Full text

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Giovanni Fucà, Romain Cohen, Sara Lonardi et al. · Journal for ImmunoTherapy of Cancer · 2022 · 107 citations · Full text

The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors

Francesca Corti, Sara Lonardi, Rossana Intini et al. · European Journal of Cancer · 2021 · 102 citations

Pan-immune-inflammation Value, Cancer Immunosurveillance, Medicine +12

Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer

Margherita Ambrosini, Benoı̂t Rousseau, Paolo Manca et al. · Annals of Oncology · 2024 · 56 citations · Full text